Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

723
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
723
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

777
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
777
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

742
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
742
Neural Regulation01:37

Neural Regulation

44.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.1K
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

1.1K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Importance of Residency Training for the Provision of Comprehensive Clinical Pharmacy Services.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Blood pressure variability in the ATACH2 study: evaluating a target range.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Prevalence and prediction of augmented renal clearance in the neurocritical care population.

Journal of neurocritical care·2026
Same author

Evaluating PICO framework utilization in pharmacy resident research.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Pharmacy, family, and faith: Our story of commitment and mentorship.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC Study.

Neurocritical care·2025

Related Experiment Video

Updated: Mar 17, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K

Neuroleptic Malignant Syndrome.

Dominic J Pileggi1, Aaron M Cook1,2

  • 11 University of Kentucky Chandler Medical Center, Lexington, KY, USA.

The Annals of Pharmacotherapy
|July 18, 2016
PubMed
Summary

Neuroleptic Malignant Syndrome (NMS) is a rare but serious drug reaction. Treatment involves stopping the neuroleptic, supportive care, and medication; rechallenging requires caution and close monitoring.

Keywords:
adverse drug reactionscritical caremanagementneurolepticsneuropharmacologywithdrawal

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K

Related Experiment Videos

Last Updated: Mar 17, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K

Area of Science:

  • Pharmacology
  • Neurology
  • Critical Care Medicine

Background:

  • Neuroleptic Malignant Syndrome (NMS) is a rare, life-threatening adverse drug reaction to antipsychotic medications.
  • Characterized by hyperthermia, muscle rigidity, autonomic instability, and altered mental status, NMS requires prompt recognition and management.
  • The incidence of NMS is reported between 0.02% and 0.03%, with a significant mortality rate of 5.6%.

Purpose of the Study:

  • To review existing evidence on the treatment of Neuroleptic Malignant Syndrome (NMS).
  • To provide guidance on the safe rechallenge of patients with neuroleptics when continued pharmacotherapy for chronic psychological conditions is necessary.
  • To summarize reported dosing strategies and outcomes for NMS pharmacotherapy.

Main Methods:

  • A comprehensive PubMed search was conducted using relevant MeSH terms and keywords, including "neuroleptic malignant syndrome," "treatment," "dantrolene," and "bromocriptine."
  • A manual review of reference sections from identified articles was performed.
  • Case reports and case series in English discussing NMS treatment and neuroleptic rechallenge were included.

Main Results:

  • Literature on NMS is predominantly retrospective, focusing on diagnostic criteria, causative agents, and treatment options.
  • Details regarding pharmacotherapy administration, dosage, and duration are inconsistently reported in current literature.
  • While infrequent, reported instances of neuroleptic rechallenge indicate a potential for recurrence even after NMS resolution, necessitating careful consideration.

Conclusions:

  • Neuroleptic Malignant Syndrome (NMS) is a rare but severe adverse drug reaction with complex pathophysiology.
  • The primary treatment for NMS involves immediate discontinuation of the causative antipsychotic agent, followed by supportive care and pharmacotherapy.
  • Antipsychotic rechallenge, when necessary, should only be attempted after a drug-free interval, using an alternative agent, with gradual dose titration and vigilant monitoring for recurrence.